INDOCO REMEDIES LTD. - 532612 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JAYSHANKAR MENONDesignation :- Company Secretary and Compliance Officer INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Quarterly Results -31.12.2019
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2020 ,inter alia, to consider and approve Unaudited Financial Results for the quarter ended December 31, 2019 Company news: Indoco Remedies
Indoco Remedies received final approval for its ANDA for Febuxostat tablets 40 mg and 80 mg, which is therapeutically equivalent to the drug manufactu
Indoco Remedies share price climbs 2% on USFDA nod
Hyperuricemia can cause kidney disease and kidney stones as well. Indoco Remedies Ltd - 532612 - Closure of Trading Window
Closure of Trading Window for dealing in Shares of the Company INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco receives Approval for Febuxostat Tablets from USFDA
Indoco Remedies gets UK health regulator nod for Goa facility; share price gains 6%
UK MHRA conducted inspection of the facility during September 16-20 this year. Indoco Remedies share price climbs 6% after FDA all-clear for Hyderabad unit
Indoco said the inspection was successfully conducted without any observations. Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco's CRO - AnaCipher receives EIR from USFDA